HMGB1 and metabolic syndrome: Our results that galantamine treatment reduced inflammatory cytokines (TNF-α, IL-6, HMGB-1), improved insulin resistance and glycemic control in the db/db mice are consistent with those of the clinical trial of galantamine in patients with metabolic syndrome.